The MCLC clinical trials database is not a comprehensive list. However, the goal is to have as current, complete and accurate a list as possible. As more information is gathered, new trials will be added to the list. To explore the current list of clinical trials, please search below.
Search by typing in the name of the city, state, country, or institution. OR search by disease status.
|
| Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for MCL |
| II-Evaluation of effectiveness & side effects |
| Newly Diagnosed/Not Previously Treated |
| Targeted to MCL |
| (650) 725-4968 |
| josho@stanford.edu |
| NIH PPG PO1 DK53005 |
| NCT00490529 |
| Levy |
| Ronald |
| Professor |
| Chairman, Division of Oncology |
| Stanford University Medical Center |
| 269 Campus Dr mc - 5151 |
| Stanford |
| CA |
| 94305 |
| US |
| (650) 725-6452 |
| (650) 736-1454 |
| josho@stanford.edu |
| Emily |
| Troutner |
| Research Coordinator |
| (650) 725-4968 |
| troutner@stanford.edu |
| 08/19/2009 |
| Stanford University Medical Center |
| Recruiting |
| II-IV |
| all |
| Not Specified (Any) |
| 30 |
The purpose of this study is to demonstrate that this combination of personalized anti-cancer vaccination and stem cell transplant can cause patients' to develop an "anti-cancer" immune system and live longer than patients previously treated with stem cell transplant alone.
|
| Patients must undergo biopsy at Stanford University PRIOR to starting any therapy. Patients are treated with: 1 - standard chemotherapy 2 - a personalized anti-cancer vaccine, then 3 - autologous stem cell transplant combined with anti-tumor T cells ('immunotransplant'). |
| 1 - Patients must undergo biopsy at Stanford prior to starting therapy.
2 - Patients must be eligible for autologous stem cell transplant (under age 71 and in good health) |
| Treatment |
| http://clinicaltrials.gov/ct2/show/NCT00490529 |
|
